MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
Read SourceMacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
Read SourceFor press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org